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CC4 human keratinocytes are derived from a squamous
cell carcinoma of the tongue and undergo very little
spontaneous differentiation. Introduction of a wild-type
 
 
 
1 integrin subunit into SCC4 cells stimulates differentiation,
suggesting either that the cells have a defect in the integrin
signaling pathways that control differentiation or that the
 
 
 
1 subunit itself is defective. Here we describe a heterozy-
gous mutation in the SCC4 
 
 
 
1 subunit. The mutation,
T188I, maps to the I-like domain. It results in constitutive
activation of ligand binding, irrespective of the partner 
 
 
 
subunit, in solid phase assays with recombinant protein
and in living cells. The mutation promotes cell spreading,
S
 
but not proliferation, motility, or invasiveness. It results in
sustained activation of Erk MAPK independent of cell
spreading. When introduced into SCC4 keratinocytes, the
wild-type 
 
 
 
1 integrin stimulates differentiation, whereas
the mutant is inactive. Activation of 
 
 
 
1 integrins in normal
keratinocytes also suppresses differentiation. These results
establish, for the ﬁrst time, mutation as a mechanism by
which integrins can contribute to neoplasia, because the
degree of differentiation in epithelial cancers is inversely
correlated with prognosis. They also provide new insights
into how integrins regulate keratinocyte differentiation.
 
Introduction
 
Integrin extracellular matrix receptors regulate growth and
differentiation of many cell types, including epidermal kera-
tinocytes (Giancotti and Ruoslahti, 1999; van der Flier and
Sonnenberg, 2001; Watt, 2002). Integrin loss or overexpression
contributes to the pathogenesis of benign epidermal disorders,
such as psoriasis, and influences the incidence and prognosis
of squamous cell carcinomas and other tumors (Mercurio
and Rabinovitz, 2001; Watt, 2002). Integrin mutations
underlie several heritable disorders, including the epidermal
blistering disease epidermolysis bullosa (Hogg and Bates,
2000), and there is growing evidence that integrin polymor-
phisms predispose to certain diseases (Kunicki, 2001). How-
ever, to date, no integrin mutations in tumors of any origin
have been reported.
When cultured epidermal keratinocytes are deprived of
contact with an adhesive substratum, they initiate terminal
differentiation. This can be partly inhibited by ligation of
 
 
 
1 integrins with antibodies or high concentrations of extra-
cellular matrix proteins (Adams and Watt, 1989; Watt,
2002). To investigate the mechanism by which integrins
regulate differentiation, we have previously introduced a series
of wild-type and mutant chick 
 
 
 
1 integrin subunits into
primary human keratinocytes and tested the ability of chick-
specific anti-integrin antibodies to block suspension-induced
terminal differentiation (Levy et al., 2000). Those studies
established that the differentiation signal can still be trans-
duced by 
 
 
 
1 cytoplasmic domain mutants that fail to localize
to focal adhesions. A point mutation that abolishes 
 
 
 
1
ligand binding is inactive in regulating suspension-induced
differentiation and this led us to conclude that the differen-
tiation signal is “do not differentiate,” transduced by ligand-
occupied receptors, rather than “do differentiate,” transduced
by unoccupied receptors.
Introduction of the wild-type chick 
 
 
 
1 subunit into primary
human keratinocytes has no effect on the proportion of cells
that undergo spontaneous terminal differentiation; this is
also true for several lines of human keratinocytes derived
from squamous cell carcinomas (Levy et al., 2000). However,
transduction of one such line, SCC4, does have a strong
positive effect on differentiation (Levy et al., 2000). SCC4
are derived from a squamous cell carcinoma of the tongue
(Rheinwald and Beckett, 1981). They are poorly differentiated,
with only 1% of cells expressing the terminal differentiation
marker, involucrin, in culture (Levy et al., 2000). Introduction
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of the wild-type 
 
 
 
1 subunit into SCC4 cells increases the
percentage of involucrin-positive cells to 
 
 
 
10%, which is
similar to the percentage in preconfluent primary kerati-
nocytes (Levy et al., 2000).
Because poorly differentiated squamous cell carcinomas
have a worse prognosis than tumors exhibiting a moderate
or high degree of differentiation (Lacy et al., 1999; Petter
and Haustein, 2000), the nature of the differentiation defect
in SCC4 cells could have broad significance for our under-
standing of how integrins influence the course of the disease.
The failure of SCC4 cells to differentiate does not reflect in-
tegrin loss or overexpression, because the level and range of
integrins (predominantly 
 
 
 
2
 
 
 
1, 
 
 
 
3
 
 
 
1, 
 
 
 
5
 
 
 
1, 
 
 
 
6
 
 
 
4, and
 
 
 
v
 
 
 
5) expressed are similar to primary human keratinocytes
(Levy et al., 2000). To test the hypothesis that the SCC4 
 
 
 
1
integrin subunit is inherently defective in differentiation
control, we sequenced the complete 
 
 
 
1 cDNA. Here we de-
scribe a point mutation in the 
 
 
 
1 subunit and report on its
functional consequences.
 
Results
 
Identification of the mutation
 
SCC4 keratinocytes were heterozygous for a point mutation
within the I-like domain of the 
 
 
 
1 subunit, T188I (Fig. 1).
The equivalent region was sequenced from 18 normal indi-
viduals. Because none of these contained the mutation, we
 
excluded the possibility of a polymorphism. We also se-
quenced the 
 
 
 
1 subunit from three squamous cell carcinoma
lines previously shown not to differentiate when transduced
with the wild-type chick 
 
 
 
1 subunit (Levy et al., 2000) and
found that they were all homozygous for the wild-type hu-
man 
 
 
 
1 sequence. Threonine 188 lies on the upper surface
of the I-like domain on a loop that projects from the surface
containing the MIDAS (metal ion–dependent adhesion site)
and ADMIDAS (adjacent to MIDAS) sites (Xiong et al.,
2001) (Fig. 1 a). The loop is a small cysteine-bridged struc-
ture present in all 
 
 
 
 subunits except 
 
 
 
4 (Fig. 1 b). This re-
gion, the “specificity loop,” is involved in ligand binding
and, when exchanged between 
 
 
 
1 and 
 
 
 
3, determines the
ligand specificity of the corresponding 
 
 
 
v heterodimers
(Takagi et al., 1997). In 
 
 
 
v
 
 
 
3, the specificity loop is dis-
placed over 1.5 Å on ligand binding (Xiong et al., 2002).
 
The T188I mutation increases the ligand binding ability 
of recombinant 
 
 
 
1 integrins
 
To study the functional significance of the mutation, we ex-
pressed it as a soluble Fc fusion protein in combination with
the 
 
 
 
5 and 
 
 
 
v integrin subunits (Fig. 2). The Fc chimeric
integrins contained the extracellular domain of each subunit
fused to the human 
 
 
 
1 immunoglobulin Fc domain and
were recovered from the medium of transiently transfected
mammalian cells (Stephens et al., 2000). The binding of
wild-type and mutant 
 
 
 
5
 
 
 
1 and 
 
 
 
v
 
 
 
1 to 2 
 
 
 
g/ml fibronec-
tin in the presence of 1 mM magnesium ions was examined.
At all concentrations tested, the heterodimers containing
the T188I mutant 
 
 
 
1 subunit showed increased binding to fi-
bronectin relative to heterodimers containing the wild-type 
 
 
 
1
subunit. In the case of 
 
 
 
5
 
 
 
1 (Fig. 2 a), the curves approached
a plateau at the highest concentration tested; this allowed us to
obtain an estimate of the relative affinity of the mutant and
wild-type heterodimers for fibronectin. The concentration of
wild-type 
 
 
 
5
 
 
 
1 that gave 50% binding was 175.9 ng/ml,
compared with 37.9 ng/ml in the case of T188I 
 
 
 
5
 
 
 
1. This
suggests that the mutant increased the affinity of 
 
 
 
5
 
 
 
1 for fi-
bronectin 4.6-fold relative to the wild-type integrin.
Figure 1. Location of the T188I mutation. (a) The predicted 
structure of the  1 I-like domain, based on comparison with the  3 
subunit using the SWISS-MODEL server and SwissPDB Viewer 
(www.expasy.org), is shown in two orientations. The threonine 188 
residue (arrowhead) lies within the specificity loop, above the 
surface containing the MIDAS (metal ion–dependent adhesion site) 
and ADMIDAS (adjacent to MIDAS) sites.   sheets are shown in 
yellow and   helices in red. The ADMIDAS cation is shown in blue. 
(b) Position and sequence comparison of the T188I-containing loop 
in  1 and other   subunits.
Figure 2. Increased ligand binding by T188I mutant relative to 
wild-type recombinant  1 integrins. Dose response curves of binding 
to 2  g/ml fibronectin by soluble  -Fc/ -Fc fusion proteins in the 
presence of 1 mM Mg
2 . (a)  5 1; (b)  v 1. Data are means and 
SEM of duplicate wells.T
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The affinity of recombinant 
 
 
 
v
 
 
 
1 for fibronectin is
lower than that of 
 
 
 
5
 
 
 
1, and the transfection efficiency of
the 
 
 
 
v
 
 
 
1 Fc chimeras was also lower (Fig. 2 b; unpub-
lished data). Hence, it was not possible to obtain an indica-
tion of the relative affinity of mutant and wild-type 
 
 
 
v
 
 
 
1
for fibronectin. Nevertheless, over a broad range of concen-
trations, T188I 
 
 
 
v
 
 
 
1 showed increased binding to fi-
bronectin when compared with wild-type 
 
 
 
v
 
 
 
1 (Fig. 2 b).
The solid phase assays thus demonstrate that T188I in-
creased the binding of two different 
 
 
 
1 integrin het-
erodimers to fibronectin.
 
The T188I mutation promotes 
 
 
 
1 integrin–mediated 
adhesion to a greater extent than the wild-type subunit
 
Threonine 188 is conserved between human and chick 
 
 
 
1,
and to compare the T188I mutation with the wild-type sub-
unit in intact cells, we engineered the mutation in the chick
 
 
 
1 subunit. We used the chick subunit to allow detection
with species-specific antibodies in both human and mouse
cells. The wild-type chick 
 
 
 
1 subunit forms functional het-
erodimers with human 
 
 
 
2, 
 
 
 
3, and 
 
 
 
5 in primary human
keratinocytes and behaves in the same way as human 
 
 
 
1 in
assays of keratinocyte differentiation, extracellular matrix ad-
hesion, and Erk MAPK activation (Levy et al., 1998, 2000;
Zhu et al., 1999).
A 
 
 
 
1-null mouse embryo fibroblast cell line, GD25
(Wennerberg et al., 1996), was retrovirally transduced with
either the wild-type (Fig. 3 a) or mutant (Fig. 3 b) integrin.
The use of high titre retroviral packaging cells enabled us to
study mixed populations, avoiding clonal selection (Levy et
al., 1998). The level of cell surface expression of wild-type
and T188I  1 was the same (Fig. 3, a and b). Parental
GD25 cells express only the  v 3 integrin (vitronectin re-
ceptor); when the  1 subunit is introduced, it is expressed as
heterodimers with  3 and  6 (laminin receptors) and with
 5 (fibronectin receptor) (Wennerberg et al., 1996).
The parental cells showed little adhesion to fibronectin or
laminin in the absence of divalent cations or in the presence
of magnesium, manganese, or calcium ions (Fig. 3, c and
d). The wild-type subunit conferred adhesiveness to both
ligands, but cells expressing the T188I mutant had a greater
ability to bind fibronectin than cells expressing the wild-type
subunit in the presence of each cation (P   0.05; Fig. 3 c).
The increased adhesion to fibronectin was observed at all
concentrations tested between 2.5 and 20  g/ml; on 2.5  g/
ml fibronectin, there was no attachment of GD25 cells ex-
Figure 3. Increased ligand binding by T188I 
mutant relative to wild-type  1 integrins in 
whole cell adhesion assays. (a and b) Flow 
cytometry of parental GD25 cells (gray lines) 
or GD25 cells transduced with (a) wild-type 
(WT) or (b) mutant (T188I) chick  1 integrin 
subunits (black lines) stained with antibody to 
chick  1 (JG22). (c and d) Adhesion of  1-null 
parental GD25 cells or GD25 transduced 
with wild-type (GD25c 1wt) or mutant 
(GD25c 1T188I)  1 integrin subunits to (c) 
10  g/ml fibronectin (Fn) or (d) 10  g/ml 
laminin (Ln) in TBS (black bars), 10 mM Mg
2  
(white bars), 1 mM Mn
2  (horizontal striped 
bars), or 1 mM Ca
2  (diagonal striped bars). 
Error bars are the SD of triplicate wells. Asterisks 
indicate conditions under which T188I-
expressing cells were more adhesive than 
cells expressing wild-type  1 (P   0.05).
Figure 4. Integrin activation and 
increased adhesiveness of SCC4 
keratinocytes. (a and b) Adhesion of 
SCC4 and SCC13 keratinocytes to (a) 
10  g/ml fibronectin (Fn) or (b) 10  g/ml 
collagen (Col) in TBS (black bars), 10 mM 
Mg
2  (white bars), or 1 mM Mn
2  
(horizontal striped bars). Error bars are the 
SD of triplicate wells. Asterisks indicate 
conditions under which SCC4 were more 
adhesive than SCC13 cells (P   0.05). 
(c) Flow cytometry of Molt4 cells, primary 
human keratinocytes (K), and SCC4 cells 
stained with phycoerythrin-conjugated 
HUTS-21 (BD Biosciences) in the 
presence of 10 mM Mg
2  (gray lines) or 
1 mM Mn
2  (black lines).T
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pressing the wild-type integrin, whereas there was one-third
maximal attachment of cells expressing the mutant (un-
published data). Maximal attachment of cells expressing
wild-type or mutant  1 occurred at  5  g/ml fibronectin
(unpublished data). In magnesium or calcium ions, the wild-
type and mutant  1 subunits promoted laminin adhesion
equally; however, in manganese, T188I promoted adhesion
to a greater extent (P   0.05; Fig. 3 d). The results support
the conclusion from the solid phase assays that T188I in-
creases the ligand binding ability of  1 integrins.
Enhanced ligand binding and ligand-independent  1 
activation in SCC4 cells compared with keratinocytes 
homozygous for wild-type  1 integrin subunit
In the solid phase and GD25 assays, the T188I mutation
promoted ligand binding when tested in the absence of
wild-type  1. Because SCC4 cells are heterozygous for the
mutation, we examined whether the mutant also promoted
adhesion when coexpressed with the wild-type subunit. We
compared the adhesion of SCC4 cells with other squamous
cell carcinoma–derived keratinocytes (SCC13) that are ho-
mozygous for wild-type  1. In the presence of magnesium
or manganese ions, the proportion of SCC4 cells that ad-
hered to fibronectin or collagen was significantly greater
than the proportion of SCC13 cells (P   0.05; Fig. 4, a and
b). Thus, T188I promoted adhesion when expressed as the
sole form of  1 (Fig. 2; Fig. 3, c and d) or when coexpressed
with wild-type  1 (Fig. 4, a and b).
As a further measure of the activation status of  1 inte-
grins containing the T188I mutation, we performed flow
cytometry of primary keratinocytes and SCC4 cells labeled
with HUTS-21, an antibody that detects a high-affinity  1
conformation (Luque et al., 1996) (Fig. 4 c). MOLT4 cells,
a lymphoblast cell line, express high levels of the HUTS-21
epitope in the presence of manganese ions and therefore
served as a positive control. The epitope was undetectable in
any strain of normal keratinocytes (cells from five individu-
als tested) and in three SCC lines expressing wild-type  1
subunits (Fig. 4 c; unpublished data). However, SCC4 cells
bound HUTS-21 in the presence of manganese. Thus, kera-
tinocytes heterozygous for T188I expressed a  1 activation
epitope in the absence of ligand, whereas keratinocytes ho-
mozygous for wild-type  1 did not (Bishop et al., 1998).
Effects of the T188I mutation on cell behavior
To study the effects of the T188I mutation on cell behavior,
we monitored the spreading, motility, and invasiveness of
parental GD25 cells and cells transduced with the wild-type
or mutant  1 subunit (Figs. 5 and 6). Both the wild-type
and mutant integrins localized to focal adhesions (Fig. 5 a),
but the mutant promoted more rapid cell spreading than the
wild type (Fig. 5 b). Both forms of the  1 subunit promoted
the random motility of GD25 cells on fibronectin equally
(P   0.34; Fig. 6, a and b). The wild-type subunit pro-
moted invasiveness through Matrigel to a greater extent than
the mutant (Fig. 6 c), probably reflecting the inverse rela-
tionship between integrin affinity and the optimal ligand
concentration for cell movement (Palecek et al., 1997).
To determine whether the mutation had any effect on in-
tegrin signaling, we examined activation of Erk MAPK in
GD25 cells expressing mutant or wild-type  1 (Fig. 5 c).  1
signaling through MAPK is known to suppress the initiation
of terminal differentiation in normal human keratinocytes
(Zhu et al., 1999; Haase et al., 2001). When GD25 cells
were plated on fibronectin in the presence of EGF, Erk
Figure 5. Effects of wild-type and T188I mutant  1 subunits on 
spreading and Erk MAPK activation of GD25 cells. (a) Both the 
T188I and the wild-type (WT)  1 subunits localized to focal adhesions. 
Cells were stained with V2E9 (anti–chick  1 integrin, green), TRITC–
phalloidin (red), and Hoescht nuclear stain (blue). Bars, 10  m. 
(b) Rate of spreading on 10  g/ml fibronectin. 50% of cells expressing 
the T188I subunit (triangles) began to spread within 10 min of 
plating, whereas cells expressing the wild-type  1 subunit (squares) 
took  20 min to achieve the same degree of spreading. By 50 min, 
 40% of the parental GD25 cells (circles) had started to spread. 
(c) Activation of Erk MAPK by plating cells on 10  g/ml fibronectin 
for the number of minutes shown, in the presence or absence of 
10 ng/ml EGF. p, phosphorylated Erk; t, total Erk.T
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MAPK was activated for longer in cells expressing the mu-
tant than in cells expressing the wild-type  1 subunit. This
was independent of cell spreading, because it was evident at
40 min, after maximal spreading of cells expressing the mu-
tant had occurred (Fig. 5 b). At the 40-min time point, the
level of phosphorylated Erk relative to total Erk was 2.4-fold
higher in cells expressing mutant  1 than in cells expressing
wild-type  1. When GD25 cells were plated on fibronectin
in the absence of EGF, the initial peak of Erk MAPK activa-
tion (7 min) was 1.9-fold greater in cells expressing T188I
than in those expressing wild-type  1 (Fig. 5 c); again this
was independent of cell spreading, because it occurred at a
time when neither population of cells had spread apprecia-
bly (unpublished data). We conclude that the mutant inte-
grin is more effective at activating Erk MAPK than the wild-
type integrin, a property that is independent of its ability to
promote cell spreading.
The T188I mutation is inactive in regulating 
keratinocyte differentiation
To examine whether the T188I mutation was responsible
for the failure of SCC4 keratinocytes to undergo terminal
differentiation (Levy et al., 2000), SCC4 cells were trans-
duced with the wild-type or T188I mutant chick  1 inte-
grin. The level of expression of each chick integrin subunit,
determined using species-specific antibodies, was equivalent
and corresponded to that of the endogenous subunits (Fig. 7
a; Levy et al., 2000). Neither subunit had any major effect
on the growth rate of SCC4 cells (Fig. 7 b). However,
whereas the wild-type subunit stimulated terminal differen-
tiation (as measured by the proportion of cells expressing in-
volucrin or cornifin), the mutant subunit had no effect (Fig.
7 c). To test whether activation of  1 integrins also inhib-
ited differentiation of primary keratinocytes, we incubated
preconfluent adherent cultures for 48 h with the activating
antibody TS2/16 (Takada and Puzon, 1993) or control anti-
 1 antibodies. At the end of the incubation period, the pro-
portion of differentiated keratinocytes was  13% in the
presence of control antibodies, but was only 7% in TS2/16-
treated cultures (P   0.05; Fig. 7 d). Thus antibody-induced
activation of the wild-type  1 subunit can suppress kerati-
nocyte terminal differentiation. This is consistent with the
observation that high concentrations of fibronectin can in-
hibit suspension-induced terminal differentiation of human
keratinocytes (Adams and Watt, 1989; Watt, 2002).
Discussion
The T188I mutation we have identified is remarkable for
three reasons. It is the first integrin mutation to be found in
a human tumor. It is, unlike the majority of integrin disease
mutations (Hogg and Bates, 2000), a gain of function muta-
tion, increasing the affinity of  1 integrins for a variety of
ligands. It impairs the ability of keratinocytes to undergo
terminal differentiation and thus can contribute to the neo-
plastic phenotype.
Figure 6. Motility and invasiveness of 
GD25 cells expressing wild-type or 
T188I mutant  1 integrins. 
(a and b) Random cell migration within 
24 h of plating on 10  g/ml fibronectin. 
(a) Starting (green) and final (red) positions 
of individual cells. (b) Mean speeds of 
40 cells. Error bars are the SD. (c) Number 
of cells that migrated through Matrigel 2 d 
after plating. Parental GD25 cells were 
compared with cells expressing the 
wild-type (GD25 1WT) or T188I mutant 
(GD25 1T188I) subunit. Error bars are 
the SD of triplicate wells.T
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The adhesion-promoting effect of the mutation was ob-
served when T188I was expressed as  5 1 (Fig. 2 a; Fig. 3 c;
Fig. 4 a),  v 1 (Fig. 2 b),  3 1 or  6 1 (Fig. 3 d), and
 2 1 (collagen receptor; Fig. 4 b) heterodimers. Neverthe-
less, the extent to which adhesion was activated did appear
to depend on the   partner and the assay conditions (e.g.,
Figs. 2 and 3). By modeling the  1 I-like domain on the
crystal structures of  v 3 (Xiong et al., 2001, 2002), we can
speculate about how the T188I mutation might increase
ligand binding (Fig. 1 a). The threonine may interact with
other residues to stabilize a low-affinity form of the receptor;
replacing the threonine with isoleucine might prevent this
interaction. Alternatively, the presence of isoleucine may in-
crease ligand binding by altering the normal movement of
the loop that occurs on activation.
Consistent with our observations, replacement of the  2
specificity loop with the  3 loop activates binding of  L 2
to ICAM1 (Kamata et al., 2002). Swapping the specificity
loops of the  1 and  3 subunits determines the ability of
each subunit to regulate Rho GTPases, demonstrating its
importance in translating information from ligand binding
into intracellular signaling events (Miao et al., 2002). It is
possible that in addition to, or as a consequence of, increas-
ing ligand binding, the T188I mutation might alter the in-
teractions of  1 integrins with other membrane proteins or
affect organization of the extracellular matrix (Schwartz,
2001; Leitinger and Hogg, 2002); however, this remains to
be investigated.
The evidence that T188I is indeed responsible for the fail-
ure of SCC4 to differentiate rests on the observation that
transduction of SCC4 cells with wild-type  1 increases dif-
ferentiation, whereas transduction with T188I does not
(Fig. 7 c). Furthermore, antibody-mediated activation of the
wild-type  1 subunit, to mimic the effect of the T188I mu-
tation, suppresses differentiation of normal keratinocytes
(Fig. 7 d). We have previously shown that the mechanism by
which  1 integrins regulate keratinocyte differentiation is
via occupied receptors transducing a “do not differentiate”
signal (Levy et al., 2000). The properties of the T188I muta-
tion support this conclusion, in that by strongly promoting
ligand binding, cells expressing the mutant integrin receive a
strong “do not differentiate” message. The enhanced activa-
tion of Erk MAPK by T188I independent of cell spreading
adds weight to the view that activation of this pathway
Figure 7. Effect of integrin activation 
on growth and differentiation of SCC4 
cells and normal keratinocytes. (a) Flow 
cytometry of parental SCC4 cells (gray 
lines) or SCC4 transduced with wild-
type (WT) or mutant (T188I) chick  1 
integrin subunits (black lines) stained with 
antibody to chick  1 (JG22). (b) Growth 
curves of parental SCC4 cells transduced 
with empty retroviral vector (diamonds), 
SCC4 expressing the T188I mutant  1 
subunit (triangles), and SCC4 expressing 
the wild-type  1 subunit (squares). 10
3 
cells were seeded per well in 24-well 
dishes and harvested at the time points 
shown. Error bars are the SD of triplicate 
wells. (c) Percent of SCC4 cells expressing 
the terminal differentiation markers
involucrin and cornifin in preconfluent 
cultures. Parental SCC4 cells were 
compared with cells expressing the 
empty retroviral vector (SCC4 pBp) or 
the mutant (SCC4 c 1 T188I) or wild-
type (SCC4 c 1 wt)  1 integrin subunits. 
Error bars are the SD of triplicate 
wells. (d) Primary human epidermal 
keratinocytes were seeded at 4   10
3/cm
2 
on a 3T3 feeder layer. 24 h later, the 
cells were incubated with 20  g/ml of 
the following anti–human  1 antibodies: 
TS2/16 (adhesion activating), P5D2, 
or A2B2 (inhibitory anti–human  1 
antibodies, which did not interfere with 
adhesion under these assay conditions). 
Control cells were incubated with no 
antibody (Km) or with W1B10 (chick-
specific anti- 1 antibody). 48 h later, the 
cells were harvested and the proportion 
of cells expressing involucrin or cornifin 
was determined. Error bars are the SD of 
triplicate wells. Asterisks indicate a 
significant difference between treated 
and control cells (P   0.05).T
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downstream of  1 integrins plays a role in suppressing kera-
tinocyte differentiation (Zhu et al., 1999; Haase et al.,
2001). It is interesting that the decision to differentiate ap-
pears to be an all or nothing response to relatively modest
changes in integrin-mediated adhesion, both in the case of
the T188I mutation and when a dominant negative integrin
mutation is introduced into keratinocytes (Zhu et al., 1999).
Changes in integrin expression, whether loss, de novo ex-
pression, or overexpression, are all reported to influence the
prognosis of epithelial tumors (van Waes et al., 1991; Jones
et al., 1997; Bagutti et al., 1998), the best-documented
mechanism being by promoting invasion (Giancotti and
Ruoslahti, 1999; Lochter et al., 1999; Thomas et al., 2001).
In contrast, the T188I mutation is not correlated with al-
tered integrin expression levels (Levy et al., 2000) and con-
tributes to the neoplastic phenotype by inhibiting integrin-
regulated differentiation. It is now of interest to determine
the overall frequency of integrin mutations in tumors, to un-
cover the extent to which such mutations affect the onset
and outcome of the disease.
Materials and methods
cDNA and genomic sequencing 
RNA was isolated from cultured SCC4 cells using the easyRNA protocol
(QIAGEN). A first strand cDNA was synthesized using random hexamer
primers with the Superscript2 reverse polymerase (GIBCO BRL). Three
overlapping 1-kb fragments of the coding region of the human  1 integrin
cDNA were synthesized using the PWO proofreading enzyme (Boeh-
ringer) and cloned into the pCR-Blunt vector (Invitrogen). Competent cells
were then transformed, and 10 clones were picked for each fragment and
sequenced multiple times in both the forward and reverse orientation. The
entire  1 cDNA was sequenced from six other sources of cultured human
keratinocytes: the squamous cell carcinoma lines SCC12F2, SCC12B2,
and SCC13 (Levy et al., 2000) and three strains of primary keratinocytes. A
small fragment containing the site of the mutation (corresponding to resi-
dues 673–832 of the  1 cDNA) was amplified from genomic DNA of 15
normal individuals and also sequenced.
Solid phase assays with recombinant integrins
Integrin cDNAs were cloned into the vector pEE12.2h, which contains the
human  1 Fc domain as a Sal1–EcoR1 genomic fragment. Separate vectors
encoding the extracellular regions of the human  5,  v, wild-type  1, and
T188I  1 integrin subunits were constructed, essentially as described previ-
ously (Stephens et al., 2000). The appropriate   and   integrin vectors were
transiently coexpressed in CHOL761h cells, and integrin chimeras were
captured from the culture supernatant with goat anti–human-Fc antiserum.
Solid phase binding to fibronectin-coated plates was performed as follows.
96-well plates (Nunc) were coated with the 50-kD fragment of fibronectin at
2  g/ml in 0.1 M sodium bicarbonate, pH 8.5. Plates were blocked with 5%
(wt/vol) BSA, 1% (vol/vol) Tween-20 in PBS. Supernatants containing solu-
ble integrins were pretreated with 25 mM EDTA and then extensively dia-
lyzed against 20 mM Tris-HCl, 150 mM NaCl, 1 mM MgCl2, pH 7.5. Titra-
tions of integrins were performed in 1% (wt/vol) BSA, 20 mM Tris-HCl, 150
mM NaCl, 1 mM MgCl2, pH 7.5, and incubated on the fibronectin for 2 h at
room temperature. Bound integrins were detected with an HRP-labeled goat
anti–human IgG-Fc serum (Jackson ImmunoResearch Laboratories).
Cell culture and retroviral infection 
Primary human keratinocytes and SCC4, SCC13, and GD25 cells were
cultured as described previously (Levy et al., 2000; Wennerberg et al.,
1996). The pBabe-puro  1 T188I construct was made using the pBabe-
puro chick  1 wild-type vector (Levy et al., 2000) as a template via the
Quikchange mutagenesis protocol (Stratagene). Retroviral packaging cell
lines were generated as described previously (Levy et al., 2000) or by
transfecting Phoenix packaging cells (G. Nolan, Stanford University, Stan-
ford, CA) and then using the virus-containing supernatant either to directly
infect GD25 cells or to make stable amphotropic virus AM12 producers
(Levy et al., 2000). The AM12 producer lines were used to infect SCC4
cells as described previously (Levy et al., 2000).
Cell attachment, spreading, motility, and invasion
96-well flat-bottomed assay plates (Dynex) were coated with fibronectin as
described previously (Levy et al., 2000). Preconfluent 75-cm
2 flasks of cells
were washed twice in serum-free medium and incubated with 5 ml of se-
rum-free medium containing 5  M CellTracker green dye (Molecular
Probes) for 20 min at 37 C. The cells were washed twice, placed in serum-
containing medium for a further 20 min, and then harvested. Cells were re-
suspended at 3   10
5 cells/ml in TBS containing Mg
2  (10 mM), Mn
2  (1
mM), or Ca
2  (1 mM). 100  l of cell suspension was added per well to trip-
licate wells and incubated at 37 C for 15 min. The plate was then washed
twice with TBS. The fluorescence value from each well was measured and
compared with a standard curve prepared from serial dilutions of the same
cell suspension. 
To quantitate cell motility and spreading, subconfluent cultures were
harvested and plated onto dishes coated in 10  g/ml fibronectin, at a den-
sity that allowed tracking of individual cells. The cells were filmed for 25 h.
Individual cells were tracked using Kinetic Imaging Tracking software and
the results analyzed using Mathematica (Wolfram Research). Cell spreading
was measured during the first 3 h of filming: the number of unspread cells
and the total number of cells in every third frame were recorded, and the
percentage of spread cells was calculated. Any cells that failed to spread
over the period of the film (24 h) were discounted as nonviable. 
Invasion assays were performed as described previously (Thomas et al.,
2001). GD25 cells were mixed with Matrigel (Becton Dickinson) to give a
final concentration of 3   10
5 cells/ml in a 1:2 dilution of Matrigel. 100  l
of the mixture was placed in 0.8- m pore size 24-well cell culture inserts
(Becton Dickinson) and left to gel for 1 h at 37 C. 100  l serum-free me-
dium was placed above the gel and 750  l medium containing 10% donor
calf serum was placed in the lower compartment. After 2 d, the inserts
were removed from their wells, the Matrigel was removed, and the mem-
branes were fixed in methanol and stained with crystal violet. The center
of each membrane was photographed, and the number of cells was
counted using NIH Image analysis software.
Measurement of Erk MAPK activation
GD25 cells expressing wild-type or mutant  1 integrins were plated on 10
 g/ml fibronectin in the presence or absence of 10 ng/ml EGF for various
times and then lysed and immunoblotted as described previously (Haase et
al., 2001). The antibody specific for phosphorylated Erk1/2 was purchased
from New England Biolabs, Inc., and the antibody to total Erk was from
Santa Cruz Biotechnology, Inc. Protein bands were visualized with HRP-
conjugated secondary antibodies using ECL (Amersham Biosciences). The
level of Erk phosphorylation was quantitated using the Scion Image pack-
age, dividing the value for each phosphoErk band with the value for the
corresponding total Erk band.
Cell differentiation assays
The proportion of terminally differentiated cells was determined essentially
as described previously (Levy et al., 2000). Involucrin was detected with
SY-5 or DH-1 antibodies (Levy et al., 2000) and cornifin with SQ37C, a
generous gift of A. Jetten (National Institute of Environmental Health Sci-
ences, Research Triangle Park, NC) (Fujimoto et al., 1997).
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